Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | RAC2 | P15153 | 1/20 | 0.31 |
| ▸ | RAC3 | P60763 | 1/20 | 0.31 |
| ▸ | CDC42 | P60953 | 1/20 | 0.31 |
| ▸ | RAC1 | P63000 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23177449 | 0.89 | KDM4E (0.35) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL13245653 | 0.87 | LIMK1 (0.36) | CDC7CLK1DBF4KDM4EATM | |
| SCHEMBL23177601 | 0.87 | CDC7 (0.33) | CDC7CLK1DBF4KDM4EATM | |
| SCHEMBL24988330 | 0.84 | KDM4E (0.39) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL25751948 | 0.83 | KDM4E (0.38) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL25751944 | 0.83 | KDM4E (0.38) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL23177269 | 0.83 | LIMK1 (0.30) | KDM4EATML3MBTL1 | |
| SCHEMBL23177270 | 0.82 | KDM4E (0.31) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL16482323 | 0.82 | KDM4E (0.40) | KDM4EATML3MBTL1RAC2RAC3 | |
| SCHEMBL16482384 | 0.82 | KDM4E (0.40) | KDM4EATML3MBTL1RAC2RAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11647669-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-09 | — | — | US | disclosed |
| US-11647669-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-09 | — | — | US | disclosed |
| US-20210098720-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11647669-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CYP1A1, CRY2 | CDC7 3056/4885CLK1 2614/4885DBF4 1341/4885 |
| US-20210098720-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CRY2 | CDC7 3056/4885CLK1 2614/4885DBF4 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.